actually employed with the percentage of the general population actually employed, but figures for the latter are not readily available.
Although there was no overall difference in the employment rate between the insulin dependent and non-insulin dependent patients, those taking insulin were more likely at some time to have been refused work or made redundant because of their diabetes. These differences may well relate simply to the greater cumulative employment experience of the insulin dependent patients because of the longer duration of their disorder. The insulin dependent patients were also more likely to be registered disabled, but about half of all patients on the disablement register were in employment. It would appear that at a time when unemployment is rising and perhaps causing increased morbidity, the overall employment prospects for our patients with diabetes do not differ from those of the general population. This finding is similar to that of an earlier survey, which concluded that the vast majority of diabetics had little difficulty in finding a job. ' Falciparum malaria resistant to chloroquine and fansidar: implications for prophylaxis Chloroquine resistant strains of Plasmodium falciparum have become established in east Africa since the first fully substantiated report of their existence in 1979.1 As a result Fansidar (pyrimethamine 25 mg and sulfadoxine 500 mg) has been recommended as routine antimalarial prophylaxis for this area. During the past year there have been several reports of falciparum malaria occurring in people taking Fansidar prophylaxis in east Africa together with reports of possible combined Fansidar and chloroquine resistance. ' We present a case of falciparum malaria resistant to both Fansidar and chloroquine with measurement of serum concentration of antimalarial agents before and during treatment and of in vitro chloroquine sensitivity. He had taken one tablet of Fansidar one week before his journey and continued this weekly throughout his stay. On 13 September he presented with fever, and a blood film confirmed the diagnosis of falciparum malaria. Over the next six days he received a total of 2-2 g of chloroquine base but after 10 days heavy parasitaemia was still present and he took a further 1-65 g of chloroquine base and three tablets of Fansidar. He improved somewhat but returned to the UK on 4 October, and was immediately admitted to hospital. On admission his blood film showed moderate parasitaemia (6690/,sl) and in the next 24 hours he received quinine, first intravenously then orally, and Fansidar. One week later scanty asexual parasites were still present and he took a second course of quinine followed by 2 g oxytetracycline daily for seven days. His blood was completely clear of asexual parasites on 27 October and he has remained well.
Chloroquine was measured by spectrofluorimetry, pyrimethamine by high performance quantitative thin layer chromatography, and sulfadoxine by reverse phase high pressure liquid chromatography on a C18 column with detection by absorption at 254 nm. Chloroquine in a single dose of 600 mg weekly (double the dose usually recommended) achieves serum concentrations which should be sufficient for complete suppression of RI chloroquine resistant strains of P falciparum.4 Nevertheless, after about six weeks of this regimen a steady state is reached, with peak serum concentrations (about 1200 nmol/l (04 ,ug/ml)) which in a study of patients receiving daily chloroquine for rheumatoid disease were associated with symptoms including headache and mild confusion.5 If chloroquine is taken in a dose of 300 mg twice weekly the peak serum concentration is unlikely to be within this range but antiparasitic activity is likely to be unaffected since chloroquine is concentrated in red cells.
In our opinion the most logical recommendation for antimalarial prophylaxis in non-immune persons in east Africa at the moment is chloroquine 300 mg twice weekly, since this should provide a safe and effective defence against RI chloroquine resistant strains of P falciparum. Until more is known about the determinants of toxicity this regimen should probably be followed for no more than one year. If, as seems likely, high level chloroquine resistance becomes established then Fansidar once weekly should be taken in addition to twice weekly chloroquine. 
Case report
A 29 year old man, experienced in marathon running, was admitted to hospital having collapsed after a 13 mile run in August 1982, when the temperature was 19 C, wind speed 6 knots, and humidity 300,. He had been taking antipyretics for a sore throat for one week, had a regular heavy alcohol intake, and had drunk six pints of beer the night before running. Relatives said that he had not drunk any fluids on the morning of the run and was behaving oddly five miles before the finish.
On admission to hospital he was unconscious and had peripheral cyanosis.
His temperature was 40WC, pulse 140 beats/min, blood pressure 90/30 mm Hg, and central venous pressure -7 cm water. He was shivering and had dry, hot skin. Investigations yielded normal results apart from acidosis (pH 7.33, carbon dioxide partial pressure 4-8 kPa (36 mm Hg), oxygen partial pressure 9-8 kPa (74 mm Hg), bicarbonate 18 mmol(mEq)/l). He was treated with ice packs, saline infused initially at 1 1/hour, oxygen, dexamethasone, diazepam, and chlorpromazine. Despite these measures his temperature did not fall below 38 5'C for six hours. A further two hours later oliguria developed, although central venous pressure was normal at 2 cm water after administration of three litres of saline. Sixteen hours after admission disseminated intravascular coagulation was diagnosed (thrombin time 26 s (normal 12 s) and concentrations of fibrinogen <0-8 g/l and fibrin degradation products 16-32 Hg/ml); this was treated with heparin 10 000 units every six hours, 4 units fresh frozen plasma, and 6 units platelets. His oliguria persisted, and after 40 hours he was transferred to the regional renal unit, where treatment with 300 mmol (25 g) sodium bicarbonate failed to correct his progressive acidosis. He was managed supportively, but 65 hours after the race, when the serum creatinine concentration was 780 timol/l (8-8 mg/100 ml) and disseminated intravascular coagulation was still present, he developed fatal cardiac tamponade.
Postmortem examination showed widespread haemorrhagic disruption of skeletal and cardiac muscle. The kidneys showed acute tubular necrosis with pigment and granular casts. There was considerable fatty change in the liver, with degeneration and regeneration of hepatocytes.
Comment
Heat stroke has three diagnostic features-namely, rectal temperature > 40°C, hot dry skin, and neurological signs, usually delirium, coma, and convulsions. The mortality, which averages 300,, is directly related to temperature. At high temperatures sweat glands fail to respond to acetylcholine and heat loss becomes inadequate despite increased skin blood flow. Liver and tissue damage lead to impaired haemostasis and occasionally to disseminated intravascular coagulation with fibrinolysis, and to reduced synthesis and metabolism of coagulation factors. Acute renal failure, which occurs in 25". of cases, is caused by decreased renal blood flow, circulating pigments, and thermal dama-e.
In Britain hypothermia is more common than heat exhaustion in marathons.3 Runners with either condition feel cold and shiver and are often supplied with space blankets. To prevent heat stroke races should be held at a suitable time and season. Competitors should be trained, acclimatised, and able to recognise early symptoms. They should know the risk factors and should not run if unwell.' 5 Adequate hydration before, during, and after the race is essential, as this case report shows. Spotters should be deployed along the route to identify exhausted runners and emergency facilities provided to cool patients.
Rapid reduction of core temperature and maintenance of cardiac output are essential in the immediate management of heat exhaustion. As any delay may lead to fatal complications treatment should be started at once and on site. The figure shows a treatment protocol that needs minimal skill and equipment. Flow chart for treating exhausted marathon runners.
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